King's College London

Research portal

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Research output: Contribution to journalArticlepeer-review

Chloe Pek Sang Tang, Gregory Y.h. Lip, Terry Mccormack, Alexander R. Lyon, Peter Hillmen, Sunil Iyengar, Nicolas Martinez‐calle, Nilima Parry‐jones, Piers E.m. Patten, Anna Schuh, Renata Walewska

Original languageEnglish
Pages (from-to)70-78
Number of pages9
JournalBritish Journal of Haematology
Issue number1
Early online date8 Sep 2021
Accepted/In press8 Aug 2021
E-pub ahead of print8 Sep 2021
PublishedJan 2022

Bibliographical note

Funding Information: The BSH paid the expenses incurred during the writing of this Good Practice Paper. All authors have made a declaration of interest to the BSH and Task Force Chairs which may be viewed on request. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi‐Sankyo. No fees are directly received personally. TM: speaker, advisory board or consultancy fees and/or research grants from Amgen, Bayer, Boehringer Ingelheim, Daichii‐Sankyo and Novartis. ARL: speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Astra Zeneca, Amgen, Takeda, Roche, Janssens‐Cilag Ltd, Clinigen Group, Eli Lily, Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd. PH: speaker, advisory board or consultancy fees and/or research grants from Astra Zeneca, Abbvie, Roche, Janssen Pharmaceuticals, Gilead and Pharmacyclics. SI: speaker fees, advisory board and educational grants from Gilead, Abbvie, Janssen and Takeda. NMC: speaker fees and travel support from Astra Zeneca and Abbvie. NPJ: speaker fees from Roche, educational grants from Janssen and AbbVie. PP: speaker, advisory board or consultancy fees and/or research grants from Novartis, Astra Zeneca, Abbvie, Roche, Janssens‐Cilag Ltd. and Gilead. AS: Honoraria from Janssen, Roche, Abbvie, Astra Zeneca, Beigene. Unrestricted educational grants from Astra Zeneca and Janssen. In‐kind contributions from Illumina, Oxford Nanopore Technology. RW: advisory board fees from Astra Zeneca, speaker fees from Janssen and Abbvie and educational grants from Janssen and Abbvie. CPST has no conflicts of interest to declare. Funding Information: The BSH Haemato-Oncology task force members at the time of writing this Good Practice Paper were Dr Guy Pratt (chair), Dr Nilima Parry-Jones (secretary), Dr Matthew Cullen, Dr Toby Eyre, Dr Shireen Kassam, Dr Oiliver Miles, Dr Elspeth Payne, Dr Simon Stern and Dr Alastair Whiteway. The authors would like to thank them, the BSH sounding board, the BSH guidelines committee and the UK CLL forum executive members Dr John Riches, Dr Adrian Bloor, Dr Andrew Pettitt, Dr Ben Kennedy, Dr Helen McCarthy, Dr Helen Marr, Dr Feargal, Dr Alison McCaig Queen, Dr Helen Parry and Dr George Follows for their support in preparing this Good Practice Paper.

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454